Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27531679

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2016 Oct 6
First author
Plesner T

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Plesner T
      type
      Author
    2. name
      Arkenau HT
      type
      Author
    3. name
      Gimsing P
      type
      Author
    4. name
      Krejcik J
      type
      Author
    5. name
      Lemech C
      type
      Author
    6. name
      Minnema MC
      type
      Author
    7. name
      Lassen U
      type
      Author
    8. name
      Laubach JP
      type
      Author
    9. name
      Palumbo A
      type
      Author
    10. name
      Lisby S
      type
      Author
    11. name
      Basse L
      type
      Author
    12. name
      Wang J
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Plesner T
      type
      Author
    2. name
      Arkenau HT
      type
      Author
    3. name
      Gimsing P
      type
      Author
    4. name
      Krejcik J
      type
      Author
    5. name
      Lemech C
      type
      Author
    6. name
      Minnema MC
      type
      Author
    7. name
      Lassen U
      type
      Author
    8. name
      Laubach JP
      type
      Author
    9. name
      Palumbo A
      type
      Author
    10. name
      Lisby S
      type
      Author
    11. name
      Basse L
      type
      Author
    12. name
      Wang J
      type
      Author
    bibliography ids
    1. nci-bib-34be3dba75d7b1f0f0a27797
    book metadata
    content sha256
    74d128fd6059fc7e8e1b9f0ee355022598c3662929dc96ed417a05a725b349da
    document type
    citation
    dois
    1. 10.1182/blood-2016-07-726729
    electronic publication date
    display
    2016 Aug 16
    precision
    day
    year
    2016
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:27531679
    immutable id
    pubmed:27531679@74d128fd6059fc7e8e1b9f0ee355022598c3662929dc96ed417a05a725b349da
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    14
    name
    Blood
    nlm unique id
    7603509
    pages
    1821-1828
    volume
    128
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      27531679
      provenance
      batch id
      d649bcb2d98dbbacd53c
      provider
      NCBI PubMed ESummary
      record sha256
      e62f494699a3ca0d92fd03f98018e1ddeda53f77c2c994d8b5352868c51c4622
      response sha256
      26648a40f123f366675007f51cc29befd1f9a89273ca2da87c477c54d2d15d20
      retrieved at
      2026-09-09T23:47:20.761544+00:00
      publication date
      display
      2016 Oct 6
      precision
      day
      year
      2016
      publication types
      1. Clinical Trial, Phase I
      2. Clinical Trial, Phase II
      3. Journal Article
      4. Multicenter Study
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/27531679/
      title
      Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.

      Preserved source evidence · Not medical advice